These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 8516593)

  • 21. An actuarial approach to comparing early stage and late stage lung cancer mortality and survival.
    Goldberg SW; Mulshine JL; Hagstrom D; Pyenson BS
    Popul Health Manag; 2010 Feb; 13(1):33-46. PubMed ID: 20158322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The lifetime risk of developing breast cancer.
    Feuer EJ; Wun LM; Boring CC; Flanders WD; Timmel MJ; Tong T
    J Natl Cancer Inst; 1993 Jun; 85(11):892-7. PubMed ID: 8492317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. On models for the estimation of the excess mortality hazard in case of insufficiently stratified life tables.
    Rubio FJ; Rachet B; Giorgi R; Maringe C; Belot A
    Biostatistics; 2021 Jan; 22(1):51-67. PubMed ID: 31135884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Timely disclosure of progress in long-term cancer survival: the boomerang method substantially improved estimates in a comparative study.
    Brenner H; Jansen L
    J Clin Epidemiol; 2016 Feb; 70():224-32. PubMed ID: 26456902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trends in cancer survival in the southeastern Netherlands since 1975: the Eindhoven Cancer Registry experience.
    Coebergh JW; Crommelin MA; van der Heijden LH; Hop WC; Verhagen-Teulings MT
    Health Rep; 1993; 5(1):105-10. PubMed ID: 8392876
    [No Abstract]   [Full Text] [Related]  

  • 26. Estimating benefits of screening from observational cohort studies.
    Flanders WD; Longini IM
    Stat Med; 1990 Aug; 9(8):969-80. PubMed ID: 2218198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Incidence, mortality and prevalence as indicators of cancer].
    Teppo L; Hakama M; Hakulinen T; Saxén E
    Duodecim; 1974; 90(22):1541-7. PubMed ID: 4452327
    [No Abstract]   [Full Text] [Related]  

  • 28. How should we value lives lost to cancer?
    Ramsey SD
    J Natl Cancer Inst; 2008 Dec; 100(24):1742-3. PubMed ID: 19066279
    [No Abstract]   [Full Text] [Related]  

  • 29. Bias in relative survival methods when using incorrect life-tables: lung and bladder cancer by smoking status and ethnicity in New Zealand.
    Blakely T; Soeberg M; Carter K; Costilla R; Atkinson J; Sarfati D
    Int J Cancer; 2012 Sep; 131(6):E974-82. PubMed ID: 22419246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimation of death rates in US states with small subpopulations.
    Voulgaraki A; Wei R; Kedem B
    Stat Med; 2015 May; 34(11):1940-52. PubMed ID: 25490870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Putting the risk of breast cancer in perspective.
    Phillips KA; Glendon G; Knight JA
    N Engl J Med; 1999 Jan; 340(2):141-4. PubMed ID: 9887168
    [No Abstract]   [Full Text] [Related]  

  • 32. Estimating relative survival for cancer: An analysis of bias introduced by outdated life tables.
    Ellison LF
    Health Rep; 2014 Feb; 25(2):13-9. PubMed ID: 24567246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer incidence and mortality patterns in South Eastern Europe in the last decade: gaps persist compared with the rest of Europe.
    Znaor A; van den Hurk C; Primic-Zakelj M; Agius D; Coza D; Demetriou A; Dimitrova N; Eser S; Karakilinc H; Zivkovic S; Bray F; Coebergh JW
    Eur J Cancer; 2013 May; 49(7):1683-91. PubMed ID: 23265703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Some features of the epidemiology of cancer of the larynx in Australia and Papua, New Guinea.
    Atkinson L
    Laryngoscope; 1975 Jul; 85(7):1173-84. PubMed ID: 1152566
    [No Abstract]   [Full Text] [Related]  

  • 35. The application of current lifetable methods to compare cystic fibrosis median survival internationally is limited.
    Jackson AD; Daly L; Kelleher C; Marshall BC; Quinton HB; Foley L; Fitzpatrick P
    J Cyst Fibros; 2011 Jan; 10(1):62-5. PubMed ID: 20888308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A model approach to calculate cancer prevalence from 5 years survival data for selected cancer sites in India--part II.
    Takiar R; Krishnan SK; Shah VP
    Asian Pac J Cancer Prev; 2014; 15(14):5681-4. PubMed ID: 25081685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trends in the survival of patients diagnosed with cancer in the Nordic countries 1964-2003 followed up to the end of 2006. Material and methods.
    Engholm G; Gislum M; Bray F; Hakulinen T
    Acta Oncol; 2010 Jun; 49(5):545-60. PubMed ID: 20491523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer trends in the United States--a view from Europe.
    Quinn MJ
    J Natl Cancer Inst; 2003 Sep; 95(17):1258-61. PubMed ID: 12953072
    [No Abstract]   [Full Text] [Related]  

  • 39. [Report of Cancer Incidence and Mortality in China, 2014].
    Chen WQ; Li H; Sun KX; Zheng RS; Zhang SW; Zeng HM; Zou XN; Gu XY; He J
    Zhonghua Zhong Liu Za Zhi; 2018 Jan; 40(1):5-13. PubMed ID: 29365411
    [No Abstract]   [Full Text] [Related]  

  • 40. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.
    Press DJ; Miller ME; Liederbach E; Yao K; Huo D
    Clin Exp Metastasis; 2017 Dec; 34(8):457-465. PubMed ID: 29288366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.